5.0
19. März 2021
Mitarbeiter (anonym)
Ehemaliger Mitarbeiter, mehr als 1 Jahr
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Because the company is so small, there's opportunity for recent grads to get experience in the different aspects of taking a problem like resistance to immunotherapy, from a treatment idea to clinical trials and submission to the FDA. It's a very collaborative work environment and great for somebody that's eager to learn.
Kontras
Currently still in startup phase so the future of the company relies on investor funding